FDA ANDA · ANDA202733
HEPARIN SODIUM
Sponsor: SHENZHEN TECHDOW
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA202733
TYPE
ANDA
ORIGINAL APPROVAL
2014-06-12
LATEST ACTION
2026-10-14
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
HEPARIN SODIUMPrescription
HEPARIN SODIUM 5,000 UNITS/ML · INJECTABLE · INJECTION
Approval history
2026-10-14Manufacturing (CMC) · Supplement 22 · unknownAP
2022-02-15Labeling · Supplement 13 · standardAP
2022-02-15Labeling · Supplement 11 · standardAP
2014-06-12UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →